Ingredia Acquires the Start Up Galactis Pharma
13 Mar 2014 --- Ingredia acquires 100% of Galactis Pharma shares, a company specializing in the valorization of bioactive peptides for the pharmaceutical industry. This company, established in 2011, has worked in close collaboration with university research laboratories and received various subsidies which highlighted its innovative character. “This acquisition is going to enable Ingredia to strengthen its position as a market leader in bioactive milk peptides by highlighting two of our recent patents”. Matthieu Arguillère – CEO Ingredia SA.
Bioactive peptides are natural milk components carrying various health benefits, as shown by fundamental research. Some of those benefits include digestive health, stress management or even anti-microbial qualities. Other peptides display a cholesterol-lowering action, offer immunomodulating properties, or facilitate minerals transportation. Unlike pharmaceutical molecules, they generally have no side effects.
After further clinical investigation, the acquisition of Galactis Pharma will allow Ingredia to expand its portfolio of bioactive ingredients focused on health benefits and also enter the pain management market. Ingredia Nutritional, one of the company’s business units specializes in the development and marketing of natural and innovative bioactives. It performs in the health and nutrition industry and, through its portfolio of bioactive ingredients, specifically offers Lactium, a unique patented solution to manage stress symptoms.
